The medical device maker has completed more than 40 acquisitions in recent years, helping turn it into one of the state’s ...

Endoscopy Equipment market in terms of revenue was estimated to be worth $32.3 billion in 2024 and is poised to reach $46.2 billion by 2029, growing at a CAGR of 7.4% from 2024 to ...

The global endoscopy visualization system and component market is on a growth trajectory, expected to achieve a valuation of USD 4,416.7 million by 2034. Expanding at a compound annual growth rate ...

Boston Scientific Corporation's acquisition of Axonics, Inc. for $3.7 billion expands urology offerings with innovative ...

We recently published a list of 8 Most Promising Medical Stocks According to Hedge Funds. In this article, we are going to ...

Boston Scientific BSX is gaining traction in the international markets. New regulatory approvals and accretive acquisitions ...

On Wednesday, Boston Scientific Corporation (NYSE:BSX) released the results of the primary endpoint of the ACURATE IDE trial of ACURATE neo2 Aortic Valve System for patients with severe ...

Boston Scientific continues to work closely with the U.S. Food and Drug Administration on the regulatory strategy for approval of the ACURATE valve platform in the U.S. The ACURATE neo2 Aortic ...

Peripheral Intervention Sales Growth: 10% organically in Q3 2024. Neurology Sales Growth: 10% in Q3 2024. Endoscopy Sales Growth: 7% organically in Q3 2024. Boston Scientific Corp (NYSE:BSX) reported ...

Neurology Sales Growth: 10% in Q3 2024. Endoscopy Sales Growth: 7% organically in Q3 2024. Boston Scientific Corp (NYSE:BSX) reported a 19% growth in operational sales and an 18% increase in ...